Is Aktis Oncology, Inc. (NASDAQ:AKTS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aktis Oncology, Inc. at current levels.
Targeted alpha-emitter radiopharma with a Lilly partnership and two shots on goal, trading at 35% of analyst targets ahead of a make-or-break Phase 1b readout.
Where AKTS is headed
Aktis sits in a small club of clinical-stage companies betting that actinium-225, not lutetium-177, is where targeted radiopharma actually pays off. The reason matters. Lu-177 (Novartis's Pluvicto) is a beta emitter, useful but blunt. Ac-225 throws alpha particles, roughly 400x more energetic over a path length measured in cell diameters. If you can deliver it precisely to a tumor antigen and not to healthy tissue, you have something closer to a guided missile than chemotherapy. The miniprotein chassis Aktis uses, smaller than an antibody, clears faster, which is exactly what you want when the payload is a radioactive isotope with an 11-day half-life.
Read the full Compass Direction on AKTS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $18.98).
See the full AKTS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Aktis Oncology, Inc. (NASDAQ:AKTS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aktis Oncology, Inc. at current levels. Targeted alpha-emitter radiopharma with a Lilly partnership and two shots on goal, trading at 35% of analyst targets ahead of a make-or-break Phase 1b readout.
What is AKTS's Compass Score?
Aktis Oncology, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for AKTS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the AKTS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.